azd8186

AZD8186 is an orally available, potent and selective small molecule inhibitor of the beta isoform of phosphoinositide 3-kinase (PI3Kβ), with additional activity against PI3Kδ. It acts by selectively inhibiting PI3Kβ in the PI3K/Akt/mTOR signaling pathway, leading to decreased tumor cell proliferation and induction of cell death in cancer cells expressing PI3K. This selectivity may offer improved efficacy and reduced toxicity compared to pan-PI3K inhibitors. AZD8186 has shown preclinical antitumor activity particularly in tumors with PTEN loss or PIK3CB mutations/amplifications. It has been investigated as monotherapy and in combination with other agents such as docetaxel or abiraterone acetate for advanced solid tumors including prostate cancer, triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and other PTEN-deficient/PIK3CB-mutated cancers.

Other names

1627494-13-6AIQ4OWD0RAAIQ-4OWD0RAAIQ 4OWD0RA